Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase ® , the WHO Pharmacovigilance Database.
Morgane CellierDelphine Bourneau-MartinChadi AbbaraAlexandre CrosnierLaurence LagarceAnne-Sophie GarnierRodolphe PerrotPublished in: Cancers (2023)
This study identified a new safety signal, nephrotic syndrome, for nilotinib and highlights the importance of post-marketing safety surveillance.